SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Dru " 2,130 found 🔀 AI-powered Shuffle
Trump Pressures FDA Commissioner to Approve Flavored Vapes
President Trump upbraided Food and Drug Administration Commissioner Marty Makary for not moving quickly enough to approve flavored vapes and nicotine products.
The Cost of AI Is Going Up | AI & Business for May 5
Plus, AI’s drug-discovery challenge, the capital-spending craze and Meta’s borrowing
Supreme Court abortion case could force Trump to take a public stance on mifepristone
The return of abortion to the Supreme Court is testing President Donald Trump’s strategy of avoiding the issue as the anti-abortion advocates grow increasingly frustrated that his administration hasn’t done more to crack down on access to mifepristone, the drug approved to terminate pregnancies.
The dark side of weight loss drugs: Ozempic's surprising hidden cost
GLP-1 weight-loss drugs like Ozempic and Wegovy are often celebrated as game-changing solutions—but new research reveals a surprising social twist. People who lose weight using these medications may actually face more judgment than those who lose weight through diet and exercise—or even those who don’t lose weight at all. The stigma seems rooted in a perception that these drugs are an “easy way out,” creating a double bind where individuals are judged both for their weight and for how they choose to manage it.
The scientist designing a tailored attack on glioblastoma
At UCLA, Dr. David Nathanson develops drugs that target the unique biology of glioblastoma, offering new hope for patients with this aggressive cancer.
Former IDF commander Wajdi Sarhan launches first Druze political party in decades
'Brotherhood Alliance' aims for Knesset seats and kingmaker role as Druze frustration with major parties grows; no clarity yet on alignment with coalition or opposition blocs
Oklahoma AG urges agency to let states regulate sports prediction markets
Oklahoma Attorney General Gentner Drummond is pressing federal regulators to make clear that states — not the federal government — have authority over sports-re
Supreme Court temporarily restores ability to receive abortion drug mifepristone by mail
The Supreme Court temporarily restored telehealth and mail access to the abortion pill mifepristone on Monday, responding to an emergency appeal that warned of potential chaos for patients who had appointments to access the drug.
Big Tech Targets Drug Discovery with Wave of Life Science Platforms
AWS, OpenAI, and Anthropic have all unveiled specialized AI workflows that promise to accelerate scientific discovery
What Doctors Want You to Know About Cannabis and Health
The government recently loosened medical marijuana rules. Experts separate fact from fiction about the drug’s safety and benefits.
How Republicans came to embrace psychedelic drugs
After decades of backing a “war on drugs,” the GOP has warmed to psychedelics for mental health treatment as high-profile backers and veterans tout the drugs.
Helene frayed the safety net for people who use drugs. This community wove it back together.
Harm reduction groups and health care workers helped avert the worst. But what about the next emergency?
Global Health & WASH: May 2026 Funding Opportunities (14 new opportunities!)
The May update for Global Health & WASH brings new calls that cluster around three distinct shifts: LMIC research leadership moving from funder encouragement into a hard eligibility constraint, pharmaceutical and corporate-linked funders running structurally independent education and use-inspired research portfolios at substantial scale, and AI adoption shifting decisively from speculative tool to operational capability across health and WASH systems alike. In LMIC Research Leadership as Eligibility, Not Encouragement, Wellcome anchors the dominant signal of the month with three separate major calls that all require or strongly center LMIC leadership in their basic eligibility architecture. Wellcome’s ESIC Hubs (£1.5-£1.9M per hub over 3-5 years) explicitly requires an LMIC-based lead applicant, treating Global South leadership as a design constraint rather than a participation goal. Wellcome’s Infectious Disease Clinical Trial Development Award funds transdisciplinary teams whose lead must be a mid-career or established researcher based at an organization in Africa, South Asia, or Southeast Asia. Wellcome’s larger Infectious Disease Clinical Trial Award (£1M-£8M for optimizing licensed interventions) requires the administering organization to be in eligible LMIC regions and at least 50% of applicants based there. Around Wellcome, the same pattern shows up at smaller scale and across funders: CHINNOVA channels $1M into West and Central African research institutions for climate-health work; IBRO’s Neuroscience Training Grants explicitly tier ceilings by region of residence with Africa receiving the highest amount ($5,000); IHME’s GBD Emerging Researcher Award reserves at least one of its two annual awards for an LMIC researcher; Sidaction’s HIV Cure call funds research teams across France, the Netherlands, and eligible African countries with a minimum two-country collaboration requirement. Taken together, these calls signal a meaningful shift in how research equity is being operationalized — not as encouragement language at the bottom of a call, but as a structural feature of who can lead, where the work must be administered, and what proportion of the team must be regionally rooted. In Pharma-Funded Independent Medical Education and Use-Inspired Research, the lineup this month is unusually deep. Pfizer alone runs four parallel calls under independent education and quality improvement frameworks: a Migraine and Women’s Health RFP (200K x 2-year, $500K pool), Migraine IME ($200K, $1M pool), JAK Inhibitor evidence-based education ($100K), and Maternal Vaccination HCP Education in Saudi Arabia ($75K), plus a separate Pediatric Pneumococcal Surveillance research call in Saudi Arabia ($400K per project). Novo Nordisk Foundation runs four parallel calls of its own at substantial scale: Infectious Diseases Catalyst Grants (DKK 60M pool, up to DKK 7M collaborative), Non-Diabetic Endocrinology Collaborative Grants (DKK 53M pool, DKK 5-10M per project), Pioneer Innovator Grant Health (DKK 1.1M), and Distinguished Innovator Grant Health (DKK 6.8M). LEO Foundation deploys DKK 2-4M per project for dermatology research excellence. Pfizer’s framing across calls deliberately separates the funding from product promotion, emphasizing measurable practice-relevant change and structural distance between scientific outputs and commercial activity. Novo Nordisk’s “use-inspired” hard filter pushes researchers toward a credible translation pathway from mechanism to deployable tool. The pattern: industry-aligned funders are running structurally independent portfolios at meaningful $ that fund implementation evidence, not promotion. In AI as Operational Capability, Not Speculation, several calls this month explicitly treat AI adoption as a near-term operational question with real evidence and governance requirements, rather than a speculative trend to be watched. Wellcome’s ESIC Hubs frames AI as “the accelerator” for evidence synthesis, asking hubs to translate technical innovation into adoption-ready workflows that can match real-world policy timelines. UNICEF Venture Fund’s new Climate Tech for Children’s Health call funds for-profit startups deploying AI, machine learning, and blockchain in low-resource environments, with a strict requirement that solutions must already have a working prototype with promising pilot results. The Water Research Foundation has launched two simultaneous AI calls treating reproducibility, cybersecurity guardrails, and human-in-the-loop deployments as core design constraints rather than nice-to-haves: one on GenAI and Agentic AI in water utilities ($200K), one on alternatives to water shutoffs that explicitly screens for implementation economics evidence. Nordic Innovation’s quantum technology call (NOK 4.5M) extends the same logic into life science and healthcare, demanding consortium-stage projects mature enough to test with real users. TEF-Health offers €300K in subsidized testing infrastructure for European healthcare AI and robotics SMEs. The pattern: funders are converting AI pilots into playbooks, requiring transfer evidence and risk controls before AI can move from experimentation to sector-wide operational practice. For LMIC-based researchers in infectious disease or evidence synthesis, the three Wellcome calls together represent the deepest concentration of LMIC-led research capital in recent memory — pair the Infectious Disease Clinical Trial Development Award (£200K, deadline May 19) as a strategic pipeline feeder into the larger Infectious Disease Clinical Trial Award (£1-£8M, deadline June 2), since the development award functions explicitly as a track into the larger trial scheme. For Nordic researchers, the four Novo Nordisk Foundation calls plus LEO Foundation and Nordic Innovation Quantum represent ~$30M in regional research capital this cycle, all with deadlines clustered in May-August. For WASH practitioners, the three Water Research Foundation calls together (each up to $200K) are a cluster worth reading across — one on AI deployment, one on shutoff alternatives, one rewarding applied innovation — and the strongest applicants will articulate how their work bridges utility operations to policy-relevant evidence. For US-based clinical researchers and educators, the four Pfizer calls plus the APF Portfolio’s 80+ programs form an unusually accessible recurring pipeline; APF’s prohibition on indirect costs is a meaningful structural feature for early-career applicants whose institutions might otherwise absorb significant overhead. Snapshot of New Opportunities Total Estimated Funding Pool: $100 Million+ USD The grants are organized into three categories: Open Calls: Current grant and opportunities with a deadline. Grants are listed by closing date. 39 open opportunities- 14 new! Rolling Applications: current grant and opportunities with rolling applications (but it’s still best to submit as early as possible). 14 rolling opportunities- 1 new opportunity! Long term planning: Grants that have closed their current rounds, but are expected to open new windows. 4 long term opportunities! A quick tip for returning readers: if you want to jump straight to the newest additions, use CTRL F to search for “New!” and navigate quickly to the latest funding opportunities This post is for paid subscribers. This helps support the time and effort it takes to curate and organize these opportunities. Subscribe To keep this accessible to everyone who needs it, we’re happy to offer pay what you can rates. You can find more details here. Open Calls: Migraine Competitive Grant Program: Migraine and Women’s Health (Quality Improvement and/or Research RFP), Pfizer.*Closing soon!* Pfizer, in collaboration with the American Headache Society, is seeking independent quality improvement and research projects that close persistent gaps in migraine care for women across the United States. The funding logic centers on measurable, practice-relevant change: proposals should generate actionable evidence, tools, or system improvements that can be shared and used widely, not just within a single site. Priority areas span menstrual migraine and screening in women’s health settings, the role of hormonal fluctuations across the lifespan, sex-specific risk factors, comorbidities and quality-of-life burden, and disparities in outcomes by race, ethnicity, and socioeconomic status. The call is structured as a two-step competitive process with an initial Letter of Intent, with the strongest concepts expected to translate scientific insight into implementable improvements in diagnosis, management, and equity. Geographies: United States. Who can apply: U.S.-based organizations (not individuals), including professional schools, healthcare institutions, professional organizations, and other entities focused on healthcare improvement. Funding amount: Up to USD $200,000 total over 2 years; total pool USD $500,000. Targeted Sectors / SDGs: Health; Focus areas: migraine, women’s health, quality improvement, clinical research, menstrual migraine, health disparities. Deadline: LOI: May 5, 2026; Full proposal (by invitation): August 28, 2026. Learn more and apply here. This RFP rewards “shareable impact”: the most competitive submissions will pair rigorous methods with a clear plan for system uptake and dissemination beyond the originating institution. ReSSARC: Strengthening the Health Sector and Food Security in the Central African Republic (AID 013381/01/0) Call for Proposals, Italian Agency for Development Cooperation (AICS). *Closing soon!* AICS is seeking a limited set of high-capacity humanitarian partners to deliver an integrated package that stabilizes essential health services while reducing acute malnutrition and strengthening food security resilience in priority areas of the Central African Republic. The funder’s logic is explicitly nexus-based: proposals should meet urgent, life-saving needs while reinforcing local systems, coordination mechanisms, and community-level capacity so results persist beyond the emergency window. AICS emphasizes inclusion and protection outcomes, expecting gender-sensitive design and explicit measures for groups facing compounded vulnerability, including women, children under five, internally displaced people, and people with disabilities. The call also signals a localization pathway, encouraging stronger collaboration with national NGOs and balanced partnerships, alongside clear coordination with existing cluster and humanitarian actors to minimize duplication and improve coverage. Geographies: Central African Republic (Bangui, Ombella-Mpoko, Ouham, Ouham-Pende, Lim-Pende, Lobaye). Who can apply: Non-profit organizations registered with AICS, plus eligible non-profits without an office in Italy that have a pre-existing collaboration agreement with an AICS-listed organization. Funding amount: Total pool EUR €1,800,000; max EUR €800,000 (single applicant) or EUR €1,000,000 (ATS). Targeted Sectors / SDGs: Health; Focus areas: malnutrition prevention and treatment, maternal and child health, community health services, food security and resilience, localization partnerships Deadline: May 5, 2026. Learn more and apply here. This call is structured to reward partners who can link frontline service delivery to system durability and localization, not just short-term coverage gains. Contracts for Innovation in drug and alcohol addiction healthcare, Innovate UK. *Closing soon!* Innovate UK, on behalf of the Office for Life Sciences Addiction Healthcare Goals program, is procuring R&D to accelerate innovations that can improve treatment outcomes, strengthen recovery, and reduce harm and deaths linked to drug and alcohol addiction. The competition is positioned as a market-facing readiness push: selected projects are expected to advance solutions toward later-stage validation, generate evidence of user acceptability and UK market fit, and map credible routes through regulatory and certification requirements. Innovate UK signals a preference for innovations that can be field-tested in relevant UK settings and progressed to TRL 6 or 7, with practical plans for commercialization after contract completion. This structure favors applicants that can execute most work in-house, co-develop with service providers and people with lived experience, and translate technical progress into deployable tools for addiction healthcare delivery. Geographies: United Kingdom. Who can apply: Single organizations of any size (including EU, EEA, or international) leading delivery, with most work and key deliverables carried out in the UK; subcontractors for specialist skills only. Funding amount: GBP £200,000–1.5 million per project (inclusive of VAT); Total pool: GBP £20 million (across two strands). Targeted Sectors / SDGs: Health; Focus areas: Mental Health, Health Systems Strengthening, Research & Development, Technology Access. Deadline: May 6, 2026 (11:00am). Learn more and apply here. This call uses procurement to pull near-market addiction innovations toward operational proof and adoption pathways in UK services.
Trophies or entertainment? Jose Mourinho conundrum facing Newcastle as Chris Waddle explains winning versus ‘boring’ balancing act
Jose Mourinho rumours refuse to go away at Newcastle, as questions are asked of Eddie Howe’s future, and Chris Waddle has told GOAL why any club considering a move for the ‘Special One’ must mull over the “win trophies or entertain” conundrum. Mourinho boasts several major honours on his glittering CV, but the ex-Chelsea and Real Madrid boss has faced accusations of being “boring” at times.
Weight loss drug Ozempic linked to lower depression and anxiety risk
GLP-1 drugs like semaglutide—best known for treating diabetes and driving weight loss under the brand names Ozempic and Wegovy—may also deliver a surprising mental health boost. In a massive study tracking nearly 100,000 people over more than a decade, researchers found that these medications were linked to significantly fewer psychiatric hospital visits and sick days.
Alzheimer’s drugs may not work and could raise brain risks
Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually help patients in any meaningful way, according to a major review of over 20,000 participants. Even more concerning, they may increase the risk of brain swelling and bleeding, sometimes without obvious symptoms.
Republicans see high-risk plans as the future of health insurance
More than 40 million Americans are already opting to take on the cost of sick visits, drugs and surgeries to get lower premiums and tax savings.
Fight over online access to abortion pill reaches Supreme Court in emergency appeal
The makers of the abortion pill mifepristone filed an emergency appeal at the Supreme Court on Saturday urging the justices to pause a lower-court ruling that temporarily blocked Americans from accessing the drug through the mail.
Scientists discover new enzyme that could supercharge weight-loss drugs
Researchers at the University of Utah have discovered an enzyme called Pap B that will chemically change and update drugs like Ozempic and Wegovy making them stronger and last longer.
Spirit Airlines shuts down after White House rescue deal falls through
The airline said early Saturday it had “no choice” but to wind down operations immediately, dashing hopes of a last-minute financial lifeline.
First malaria drug for babies is approved in ‘major public health milestone’
WHO prequalification of Coartem Baby means newborns can be safely treated rather than using medication for older children
Appeals court blocks FDA rule that allows women to obtain abortion drugs by mail
A federal appeals court temporarily reinstated a nationwide requirement that abortion pills be obtained in person, undermining access to the method of abortion that has only grown more widespread since the US Supreme Court overturned Roe v. Wade.
Surgery still outperforms GLP-1 drugs in terms of heart health
Both treatment options are effective, but metabolic and bariatric surgery was linked to more significant cardiovascular risk reductions than GLP-1 medications.
Science news: Return of the river-herring run, Musk vs. Altman and new pancreatic cancer drugs
Under the Radar breaks down the latest science and technology headlines, including communities fighting back against data centers, overheated sharks and more
FDA authorizes early access for experimental pancreatic cancer pill
The FDA said the action recognizes the dire need for a drug to improve survival for pancreatic cancer patients, who face the worst survival odds in oncology.
James Druckman elected to the National Academy of Sciences
The University of Rochester professor is a renowned expert in political polarization and American democracy.
USDA issues health alert for frozen pizza sold nationwide at Aldi stores due Salmonella concerns
A health alert has been issued by the Food & Drug Administration (FDA) for a frozen pizza brand sold nationwide at Aldi stores because of possible Salmonella contamination.
USDA issues health alert for frozen pizza sold nationwide at Aldi stores due Salmonella concerns
A health alert has been issued by the Food & Drug Administration (FDA) for a frozen pizza brand sold nationwide at Aldi stores because of possible Salmonella contamination.
Media Recap: Behavioral Health and Drug Manufacturer Pressures
Adam Carlson, senior vice president of Advocacy, MHA, joined J.J. Hodshire, president and chief executive officer, Hillsdale Hospital, for a press conference April 17 to discuss how proposed cuts to Medicaid will further destabilize hospitals already experiencing financial strain.
Big Pharma throws support behind Ashley Moody in US Senate race
A number of pharmaceutical companies had their drugs removed from a list slated for price reduction negotiations with Medicare officials, thanks to legislation that Moody supported.
An incredible NBA blowout, plus LIV’s cash burn
The Pulse Newsletter 📣 | This is The Athletic’s daily sports newsletter. Sign up here to receive The Pulse directly in your inbox. Good morning! I hope you have your hat ready for tomorrow. Coming up: 😳 A historic Knicks rout 😰 Edmonton’s conundrum 💸 LIV’s cash burn We had a flight of 3-2 series matchups in both the NBA and NHL last night. I must start with an NBA clincher, though, due to a simple staggering fact: The Knicks advanced to the second round last night after beating the Hawks, in Atlanta, by 51 points. Not a typo! This was a 50-point game in the...
Health clinics exempt from drug discount rule change
A major overhaul to a federal drug discount program Indiana officials allege is being misused to generate hospital profits will exempt dozens of clinics serving low-income Hoosiers.
Are all our politicians on drugs? No. Yet it is fair to say some may occasionally attend work refreshed
Gor blimey it smells like a brewery
PwC will drop cover for weight-loss drugs from employee health plans
Big Four accountancy balks at high cost of medication it says has become ‘cultural phenomenon’
New treatment cuts bad cholesterol by nearly 50% without statins
A new breakthrough could change how high cholesterol is treated, offering a powerful alternative to traditional drugs. Researchers have developed tiny DNA-based molecules that shut down PCSK9—a key protein that keeps “bad” LDL cholesterol circulating in the blood. By blocking this protein, cells can absorb more cholesterol instead of letting it build up in arteries, dramatically lowering levels linked to heart disease.
Britney Spears charged with driving under the influence of alcohol and drugs
Britney Spears was charged in California on Thursday with driving under the influence of drugs and alcohol, authorities said.
Britney Spears charged with driving under the influence of alcohol and drugs
Spears was charged in California Thursday
Throwing 85 mph, Brandon Woodruff leaves start in second inning
Brandon Woodruff's velocity was alarmingly low, leading to the Brewers taking him out early on April 30
Druski tapped to host BET Awards, becoming youngest emcee in show’s 25-year history
Druski will host the 2026 BET Awards, becoming the youngest emcee in the show’s history.
UChicago students propose solutions to city's sports stadium conundrum
The annual Harris Policy Innovation Challenge, launched in 2023, pushes students to find solutions to some of Chicago’s most pressing public policy issues.
Cardinal Health lifts annual profit forecast on strong demand for specialty drugs
Drug distributor Cardinal Health on Thursday raised its 2026 profit forecast range, betting on strong demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.
CEO of ECU Health urges House Ways and Means Committee to abandon "one size fits all" healthcare solutions
The leader of eastern North Carolina’s largest health system was in Washington this week, telling federal lawmakers that rural America is being left behind by current healthcare policies.
Reid Hoffman Thinks Doctors Should Ask AI for a Second Opinion
The LinkedIn cofounder now has an AI drug discovery startup—and thinks not asking chatbots for medical advice is “bordering on committing malpractice.”
Protect patient access to life-saving drugs
By Leslie Herod Since its inception, Colorado’s Prescription Drug Affordability Board (PDAB) created fear among patients around effects to life-saving medicines and the negative ramifications price controls have on affordability. Five years on, those fears persist. Patients and advocates continue to push for protections for those facing the very likely scenario drugs whose price is […]
Viewpoint: A career in science is possible, and worth it
Starting a career in science is exciting, but also demanding, with researchers often faced with intense competition, long working hours and high levels of stress. A pioneer in the field of mass spectrometry, Carol Robinson has been there. She speaks with Science|Business on the importance of creating a supportive environment, particularly for women.Robinson did not wake up one day thinking that she would become a scientist. It was only late in school that she developed an interest in chemistry. “The more you work at something, the more you think, actually, this is fascinating. So, I went much further and deeper than I ever needed to pass the exam. And then I loved it,” she says. “I thought, I’m going to give it my all. I’m going to enjoy it while I’m here. But I didn’t think this would be my career for 50 odd years.”She left school at 16 to become a lab technician with the drug company Pfizer, which is where she first worked with mass spectrometry. Fascinated, she was encouraged to take a part-time degree and then a PhD. She went on to do pioneering work in native mass spectrometry, a technique that is used to study protein structures in their natural state, paving the way for breakthroughs in drug discovery. She also broke new ground by becoming the first female professor of chemistry at the University of Cambridge, and then the first female professor of chemistry at the University of Oxford, her current home.She now wants to show young researchers that a career in science is worth it. “Sometimes, I believe the culture isn’t very encouraging, and that’s something I have worked on,” Robinson says.In 2021, she launched the Kavli Institute for Nanoscience Discovery at Oxford, whose acronym gives a sense of what she hopes it will achieve. “Maybe it is corny,” she says. “It’s just a reminder that I would like it if we could all be kind to each other and supportive, especially for early-career researchers of either gender, because there’s quite a big attrition rate in science, and maybe it just doesn’t feel like a very friendly place to work.”And yet, a career in science comes with a lot of flexibility. “There are few careers where you have that amount of freedom, to go to conferences, to the library. Just because you didn’t see me didn’t mean I wasn’t working,” she says. “And I’m excited to come in every day. So, I don’t want people to think it’s a terrible place.”Gender equality is also important when it comes to the quality of science as a career. “The more women we have, the better it becomes,” Robinson adds.Imposter syndromeAccording to EU data, women outnumber men in university education but account for just about a third of graduates in science, technology, engineering and mathematics (Stem). And while the number of women working as scientists and engineers in the 27-member bloc is on the rise, their representation remains below that of men, at 41%. This discrepancy is even more pronounced in top-tier functions across these fields, where women fill just 20% of positions.Having supervised many young scientists, Robinson sees that women continue to have a greater propensity than men to doubt their abilities, a feeling she once shared. “When I was doing my PhD at the University at Cambridge, I really felt like an imposter,” she says. “I don’t think I ever felt I deserved to be there or owned it and was proud. I just thought I was lucky.” Later on, she adds, “I was always that person who said, I can’t apply yet because my CV is not strong enough.”She has now made it her job to encourage women to break with this imposter syndrome. For example, rather than calling for volunteers to give a lecture in the groups that she mentors or teaches, which nearly always results in men stepping forward, she goes straight to the women, “because I know they won’t push themselves forward.”But the gender gap in science is not just down to imposter syndrome. The “obvious” reason, Robinson says, and the reason that is on everybody’s mind when discussing workplace gender equality, is the balance between work and raising a family. Her own path was to choose between the two, taking an eight-year break after completing a postdoctoral training fellowship to bring up three children. And she continues to advise women not to work part-time while they raise a family. “You’ll just get half the pay and continue to work full-time because you are not able to fit everything in,” she says. “You should be able to have a family and come back to have the career that you want.”The solution is for men to also take career breaks. “That kind of evens it up, so that it’s not such a big thing for women,” Robinson says. “I always encourage men in my groups to do that. I think it’s important to take your share of the duties.”Support produces resultsAccording to the Women in Stem Network, a UK advocacy group, countries with strong childcare systems and equal pay policies retain more women in technical careers. In Europe, these are primarily found in the Nordic region and parts of central Europe.At the EU level, the European Commission asks all Horizon Europe applicant organisations to have a gender action plan in place. Since this criterion was introduced in 2021, the share of women leading consortia has increased to 31%, against 23% in Horizon 2020. Their overall participation, however, has risen just 1%, to 38%. After trying to weaken the requirement for gender action plans in 2025, the Commission now intends to adopt a plan for supporting women in research and innovation.Related articlesCommission scraps plan to water down gender requirements in HorizonHow gender balance can swing who wins Horizon Europe fundingRobinson herself has benefited from three Advanced Grants from the European Research Council. “I was extremely honoured and privileged to get those, because they really allowed me to fuel my passion,” she says. “Without that, it would have been a much harder slog.”Beyond applying gender rules, she says that more work is needed on translational enterprise, where women are, once again, largely underrepresented. The European Patent Office found that only 13.8% of applications were filed by women in 2022. “We have so many more women doing amazing science; why do they feel it’s not a thing to have a company?” she asks.She founded her own spin-out company, OMass Technologies, in 2016, and remains chair of its scientific advisory board now that it trades as OMass Therapeutics. As for research, Robinson is now studying how changes in the brain may be linked to depression, using port-mortem tissue. “We’re hoping to publish soon,” she says. “We had to consult with a lot of people who knew a lot more about the brain than we did. So, we’ve learnt a lot, and that’s always a lot of fun to learn a new thing. That’s what keeps you going.”
‘The energy behind these drugs has moved from the beatniks to biohackers’
Opinion, comment and editorials of the day
They want their teams to win. The Liberty and Nets owners are funding scientific breakthroughs on human health that only billionaire philanthropy can achieve
Clara Wu Tsai's $220 million investment in athlete research has already helped lead to a drug designed to preserve muscle strength as we get older.
Ibogaine Hype Is Outpacing the Science
The hype surrounding the psychedelic drug ibogaine reached a fever pitch earlier this month, when President Donald Trump talked up its potential at a White House event promoting increased access to psychedelics. Ibogaine, which comes from the root of a West African shrub, has long been used for ceremonial and spiritual purposes. Now, for the first time, the Food and Drug Administration will allow a clinical trial of the drug.
Report: iPhone Memory Costs Set to Quadruple by 2027
Memory could account for as much as 45 percent of an iPhone's component costs by 2027, up from around 10 percent today, according to a JPMorgan analysis cited by the Financial Times ($). Apple buys memory for roughly 250 million iPhones a year and has historically been one of the largest customers in the category. But Apple has reportedly now gone from a position where it could set terms to one where it now has to compete with rivals for supply.
This ‘longevity drug’ may weaken gains from exercise
Researchers anticipated rapamycin would enhance the effects of working out, while also initiating health improvements of its own, but the results surprised them.
Australia becomes the 30th country to eliminate trachoma as a public health problem
The World Health Organization (WHO) has validated Australia for eliminating trachoma as a public health problem, marking a significant milestone in the health of indigenous peoples and in global efforts to combat neglected tropical diseases (NTDs). Trachoma, the world’s leading infectious cause of blindness, no longer represents a public health problem in the country.Australia is among a growing number of countries that have successfully eliminated trachoma, contributing to global progress towards the targets set out in the WHO road map for NTDs 2021–2030.Trachoma is caused by the bacterium Chlamydia trachomatis and spreads through close contact with infected individuals, contaminated surfaces, and flies that carry eye and nose discharge. Repeated infections can lead to scarring of the eyelids, turning eyelashes inward, and ultimately causing blindness if untreated.“WHO congratulates Australia on this important achievement,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This success reflects sustained commitment, strong partnerships, and a focus on reaching populations most affected by health inequities. It brings us closer to a world free from the suffering caused by trachoma.”Australia’s journey to eliminationAustralia’s achievement reflects decades of targeted public health action, particularly in remote Aboriginal and Torres Strait Islander communities, where trachoma persisted despite its earlier disappearance from the rest of the country.National efforts intensified with the establishment of the National Trachoma Management Programme in 2006, which implemented the WHO-recommended SAFE strategy: surgery for trichiasis, antibiotics to treat infection, promotion of facial cleanliness, and environmental improvement. Regular screening of all communities classified as at-risk of trachoma by teams of qualified health workers formed an important part of the Programme. Interventions were delivered through coordinated partnerships between federal and state governments, Aboriginal community-controlled health services, and local communities.Over time, sustained screening, treatment, and prevention activities, including improvements in housing, water, sanitation and hygiene, led to a steady decline in trachoma prevalence. Australia’s approach included adaptations to reflect its context, such as targeted treatment based on community-level data rather than mass drug administration, and strong integration with environmental health programmes.“Elimination of trachoma is a win for the eye health of communities across Australia, particularly those whose lives have been impacted by a disease that is entirely preventable,” said Mark Butler, Minister for Health and Ageing, Australia. “This major milestone is thanks to Aboriginal and Torres Strait Islander leadership, community commitment and sustained investment over many decades.“The lessons from this work will inform how we approach other preventable health conditions in remote and regional Australia. Aboriginal Community Controlled Health Organisations and local health workers have been central to this success, delivering culturally safe care and community-led solutions.”“This recognition from the World Health Organization reflects decades of work led by Aboriginal Community Controlled Health Organisations, alongside local health workers in remote First Nations communities,” said Malarndirri McCarthy, Minister for Indigenous Australians. “Their work has been critical to eliminating trachoma as a public health problem in Australia.”Advancing global efforts against neglected tropical diseases (NTDs)Trachoma is one of 21 diseases and disease groups that are regarded by WHO as NTDs. Together, NTDs affect more than 1 billion people worldwide, primarily in underserved populations with limited access to essential services such as clean water, sanitation, and health care.Australia’s elimination of trachoma as a public health problem highlights the importance of sustained political commitment and cross-sectoral collaboration in addressing the underlying determinants of health. It also underscores the feasibility of eliminating trachoma even in geographically challenging settings.In addition to trachoma, Australia has several endemic NTDs, including Buruli ulcer, leprosy and scabies. Validation of elimination of trachoma as a public health problem marks the first time that WHO has confirmed the elimination of an NTD in Australia, which becomes the 63rd country globally and 16th in the Western Pacific Region to have eliminated at least one NTD.“Tackling neglected tropical diseases in the Western Pacific Region has long been a challenge for countries across the socioeconomic spectrum, given the complexities in reaching the most vulnerable communities, including in remote areas,” said Dr Saia Ma’u Piukala, WHO Regional Director for the Western Pacific. “As a doctor from Tonga, I’ve experienced these challenges for myself. But I also know that with strategic commitment underpinned by optimal resources and partnerships in health, success is possible as other countries in our region have also demonstrated. I commend Australia on eliminating trachoma as a public health problem and urge all involved to remain vigilant to ensure this status is maintained.”WHO continues to support countries working to eliminate trachoma and other NTDs, ensuring that progress reaches those most in need and that gains are sustained through strong surveillance, appropriately integrated into national health systems, and mainstreamed within the wider health sector and beyond.Editor’s notesNeglected tropical diseases and trachoma elimination effortsNeglected tropical diseases are associated with devastating health, social and economic consequences. Their burden is mainly felt among impoverished communities in tropical areas.Public health targets for the control, elimination and eradication of these conditions were set in the road map for neglected tropical diseases 2021–2030 (https://www.who.int/publications/i/item/9789240010352).In 1996, WHO launched the WHO Alliance for the Global Elimination of Trachoma by 2020 (GET2020), creating a network of governments, non-governmental organizations and academic institutions dedicated to the fight against trachoma. WHO continues to support endemic countries to accelerate progress towards the global target of eliminating trachoma as a public health problem worldwide; 2030 is the new target date.Elimination of trachoma as a public health problem is defined as: (i) a prevalence of trachomatous trichiasis (TT) “unknown to the health system” of < 0.2% in ≥15-year-olds; and (ii) a prevalence of trachomatous inflammation—follicular (TF) in children aged 1–9 years of < 5%, in each formerly endemic district, plus (iii) the existence of a system to identify and manage incident cases of TT.Other countries validated by WHO as having eliminated trachoma as a public health problem are: Algeria, Benin, Burundi, Cambodia, China, Egypt, Fiji, Gambia, Ghana, India, Iraq, Islamic Republic of Iran, Lao People’s Democratic Republic, Libya, Malawi, Mali, Mauritania, Mexico, Morocco, Myanmar, Nepal, Oman, Pakistan, Papua New Guinea, Saudi Arabia, Senegal, Togo, Vanuatu and Viet Nam.
18 silly finalists from the Comedy Wildlife People’s Choice Awards
And your prestigious winner is...*drumroll please*...a bird with grass on its face.
Health Canada approves first generic version of Novo Nordisk's Ozempic
Health Canada has approved the first generic version of Danish drugmaker Novo Nordisk's blockbuster diabetes drug Ozempic made by Indian drugmaker Dr Reddy's Laboratories , its website showed on Tuesday.
Waldrum warns “one-size-fits-all” health policy could harm rural patients and providers
ECU Health CEO Dr. Michael Waldrum testified before a congressional committee Tuesday, urging federal lawmakers to take targeted action to address rising health
Could At-Home Brain Stimulation Reduce Psychiatry’s Reliance on S.S.R.I.s?
A headset recently approved by the Food and Drug Administration uses a weak electric current to shock the brain. Some researchers hope it could challenge the current pill-centric paradigm.
ECU Health CEO Dr. Michael Waldrum testifies before U.S. House Committee on Ways and Means on rural health care access, affordability
Dr. Michael Waldrum, CEO of ECU Health, testified before the U.S. House Committee on Ways and Means on rural health care access and affordability.
Trump administration reverses on paying for fentanyl detection strips
The Trump administration is no longer allowing federal funds to be used for purchasing or distributing test strips that can determine if street drugs ha…
Todd Bridges reveals shocking sexual encounter with Dana Plato on 'Diff'rent Strokes' set: 'How would a 12-year-old girl know about that?'
On the latest episode of 'Hollywood Demons,' Todd Bridges opened up about the troubled life of his 'Diff'rent Strokes' costar Dana Plato, including a shocking sexual encounter on set.
Paradigm Health Announces Collaboration with the FDA to Transform Regulatory Review of Clinical Trial Data
/PRNewswire/ -- Today, Paradigm Health announced the launch of a landmark research collaboration with the U.S. Food & Drug Administration (FDA) focused on...
6 Things to Do Before Taking Dietary Supplements | Live Healthy
Taking dietary supplements can help with vitamin and mineral deficiencies. But it can also put you at risk for drug interactions and vitamin overdose.
MIT scientists turn chaotic laser light into powerful brain imaging tool
Scientists at MIT discovered that chaotic laser light can spontaneously form a highly focused beam instead of scattering—if the conditions are just right. This “pencil beam” enabled them to image the blood-brain barrier in 3D at speeds 25 times faster than existing techniques. The method also lets researchers watch how drugs move into brain cells in real time. It could dramatically accelerate the development of treatments for neurological diseases.
U.S. Government Will Stop Paying for Test Strips to Detect Deadly Drugs
In a letter to states and other grant recipients, the Trump administration says the strips encourage drug use.
What to know about psychedelic retreats, a booming business
Surging interest in the purported benefits of psychedelic drugs has given rise to a new industry: psychedelic retreats
The best, boldest and most 'wait, what?' Stagecoach outfits, from Sydney Sweeney’s corset to Brittany and Patrick Mahomes' coordinated country-chic
From Sydney Sweeney's lingerie saloon moment to Post Malone's quadruple denim ensemble, the best Stagecoach looks went beyond the basics.
Trump administration warns against using federal dollars on fentanyl test strips
The Trump administration underlines a “clear shift away from harm reduction and practices” that it says facilitates illegal drug use.
DEA Will Start Accepting Applications From Medical Marijuana Businesses That Want Federal Rescheduling Protections This Week
The Drug Enforcement Administration (DEA) has announced that it will begin accepting applications this week for medical marijuana businesses to apply for federal protections being granted under the Trump administration’s cannabis rescheduling process. The agency’s “Medical Marijuana Dispensary Registration Portal” is set to go live on Wednesday at 9 AM ET. The move follows last […]
Multiple GLP-1 drugs linked to lower AFib risk
The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment.
Lawmaker calls for special session on marijuana: week in politics
As the feds officially declassified marijuana as a less dangerous drug, Nashville lawmaker calls for a special session to legalize medical cannabis.
Rodgers and Hammerstein, Lerner and Loewe musicals come to L.A.
Rodgers and Hammerstein's "Flower Drum Song" and "The Sound of Music" and Lerner and Loewe's "Brigadoon" are all running in L.A. this spring.
Drug use in England spikes during heatwaves and big sports events, research finds
Project that tested traces of illicit drugs in wastewater also found higher use during Eurovision song contest
NEO health boards host second joint professional development training
Building on a “successful partnership,” the Lake County Alcohol, Drug Addiction and Mental Health Services Board and the Ashtabula County Mental Health and Recovery Services Board recently held their second annual professional development t…
AI goldrush collides with voter backlash in Georgia
Multibillion-dollar artificial intelligence hubs are beginning to scramble politics in the crucial swing state as voters worry about costs and local control.
Patients taking weight-loss drugs often make 5 critical mistakes, doctor warns
Experts say GLP-1 drugs offer benefits beyond weight loss, but common mistakes like skipped labs and poor nutrition can undermine results or cause harm.
Graphene kills harmful bacteria “superbugs” but spares human cells
Scientists have uncovered how graphene oxide pulls off a remarkable trick: it hunts down and destroys harmful bacteria while leaving human cells completely unharmed. By targeting a molecule found only in bacterial membranes, this ultra-thin carbon-based material acts with laser-like precision—offering a powerful new alternative to traditional antibiotics. Even more exciting, it works against drug-resistant “superbugs,” promotes faster wound healing, and keeps its antibacterial strength even after repeated washing.
State of Texas: Marijuana reclassification could expand medical research
The federal government is easing restrictions on medical marijuana, reclassifying certain cannabis products from a Schedule I drug to a less restrictive Schedule III — a move that could significant…
Adams County Health Department joins Drug Take Back Day efforts
Drug Take Back Day allows anyone with unneeded medications to dispose of them safely.
What is ibogaine? FDA to fast-track review of drugs for mental health
DCSO: Suspect arrested while shipping drugs at local business
Detectives arrested 41-year-old Ryan Lehan of Owensboro while he was attempting to ship out those drugs at a local business.
What to know about psychedelic retreats, a booming business with few safety guardrails
Virtually all the drugs offered at retreats are illegal under U.S. federal law.
What to know about psychedelic retreats, a booming business with few safety guardrails
Virtually all the drugs offered at retreats are illegal under U.S. federal law.
The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
FDA fast-tracking its review of two psychedelic drugs for mental health treatments
Hallucinogenics are illegal under federal law but that isn’t stopping the FDA from fast tracking 3 psychedelic drugs to treat mental health
Last week, President Donald Trump signed an executive order directing the FDA and other federal agencies to speed research and loosen restrictions on psychedelics, a class of hallucinogenic drugs which remain illegal under federal law.
New synthetic opioid linked to overdose death in San Francisco
The drug is reportedly 10 times more potent than fentanyl.
Fact-checking RFK Jr.'s claim there's more than one way to calculate a percentage decrease
President Donald Trump has regularly said that drug-price discounts on his watch are greater than 100%, which isn’t mathematically possible. Now his health and human services secretary, Robert F. Kennedy Jr., is trying to back up his faulty math.
Popular weight loss drug linked to key benefits for patients undergoing TAVR, PCI
Two separate studies explored the value of treating heart patients with tirzepatide.
Trump Administration Approves Firing Squad Executions for Death Penalty
The Justice Department also reauthorized the use of a death penalty drug, and will seek to shorten the length of some legal appeals.
FDA moves to fast-track review of psilocybin and methylone for mental health
Some psychedelic drugs, once considered fringe, are now getting a step closer to possibly being approved for use as mental health treatments in the United States.
Big business shows up in final days of arguments at Supreme Court
Big businesses are lining up at the Supreme Court as the justices hear the final arguments of the term, pressing the conservative majority to shield industries from multimillion-dollar jury verdicts, limit the marketing of generic drugs and neuter the government’s ability to issue fines.
Big business shows up in final days of arguments at Supreme Court
Big businesses are lining up at the Supreme Court as the justices hear the final arguments of the term, pressing the conservative majority to shield industries from multimillion-dollar jury verdicts, limit the marketing of generic drugs and neuter the government’s ability to issue fines.
FDA grants quick review for 3 psychedelic drug trials
FDA commissioner Marty Makary told NBC News that the first psychedelic drug could be approved in the U.S. as soon as this summer.
News | North Carolina’s Research Triangle scores another $1 billion-plus life science campus
AbbVie’s drug manufacturing complex in Durham expected to create over 730 jobs
Marijuana's reclassification raises new questions for the cannabis industry
Medical marijuana is moving from Schedule I status, reserved for the most dangerous drugs like heroin and LSD, to Schedule III, like testosterone and steroids, which are less strictly regulated.
Reclassifying marijuana as a less dangerous drug might only be the first step for Trump
President Donald Trump’s decision to reclassify state-licensed medical marijuana as a less dangerous drug is a boon for the industry.
Could ibogaine, a psychedelic drug, improve Americans' mental health? Some Coloradans says yes
Twisted nanoparticles sorted by light
Chiral objects are important in fields like drug development because their interactions with biological systems depend on handedness. Researchers from Tokyo University of Science, Institute for Molecular Science, and Seoul National University used light to selectively manipulate nanosized chiral objects. By confining circularly polarized light in an ultra-thin optical fiber, they transported metallic chiral nanoparticles based on handedness, thereby enabling chirality control at near-molecular scales, opening possibilities for applications involving chiral systems, including drug development.
'Big Business Opportunity': Cannabis CEO Celebrates DOJ Easing Regulations On Medical Marijuana
The Trump administration reclassified medical marijuana as a less dangerous drug on Thursday.
Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
President Donald Trump on Thursday announced a deal with drugmaker Regeneron to lower the cost of its pharmaceutical products as part of the White House’s signature drug pricing initiative.
What You Need to Know About the Health Risks of Marijuana
Studies show the drug can exacerbate anxiety and teen use poses risks for developing brains.